First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans
Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc (LSE: BTG) have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver. The trial will evaluate delivering a precisely controlled dose of vandetanib, an inhibitor of multiple tumour growth pathways, directly to the arteries feeding a liver tumour by pre-loading the drug on a radiopaque bead which can be visualised on CT scans.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063